Nonetheless, it is widely believed that inhibiting the formation of Aβ, either by inhibiting BACE-1 or γ-secretase would be of benefit for AD patients, regardless which Aβ assembly is the neurotoxic agent. The gene discussed is BACE1; the disease is Alzheimer disease.